Summary of Use during Lactation

No information is available on the clinical use of rucaparib during breastfeeding. The manufacturer recommends that breastfeeding be discontinued during rucaparib therapy and for 2 weeks after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Name

Rucaparib

CAS Registry Number

283173-50-2

Drug Class

Breast Feeding

Lactation

Milk, Human

Antineoplastic Agents

Enzyme Inhibitors

Signal Transduction Inhibitors

PARP Inhibitors